CIA
XENE icon

Cape Investment Advisory’s Xenon Pharmaceuticals XENE Stock Holding History

Cape Investment Advisory’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29K Buy
+38
New +$2.11K ﹤0.01% 1216
2026
Q1 		– Sell
-39
Closed -$1.75K – 1232
2025
Q4 		$1.75K Hold
39
– – ﹤0.01% 1124
2025
Q3 		$1.57K Hold
39
– – ﹤0.01% 702
2025
Q2 		$1.22K Buy
+39
New +$1.27K ﹤0.01% 1012

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Cape Investment Advisory's XENE Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 38 shares worth $2.29K. The stake represents ﹤0.01% of the portfolio and ranks #1216 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in XENE as recently as Q4 2025.

Cape Investment Advisory first reported a position in XENE in Q2 2025 and has held it in 4 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Cape Investment Advisory held 38 shares of Xenon Pharmaceuticals worth $2.29K as of Q2 2026.
  • Xenon Pharmaceuticals was a new Cape Investment Advisory position in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1216 holding.
  • Cape Investment Advisory first reported a position in Xenon Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.